Advances in Frontline Gastric, GEJ, and Esophageal Adenocarcinoma From ESMO 2025 - Episode 3
Detailing the Ongoing Phase 3 STAR-221 Trial of Domvanalimab/Zimberelimab Plus FOLFOX in First-Line Gastric/GEJ/Esophageal Adenocarcinoma
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.
Related Content:
